Fig. 3

KRAS Mutational Status on OS by Treatment in (A) the 1L* and (B) the 2L^†. 1L, first line; 2L, second line; aHR, adjusted hazard ratio; CIT, cancer immunotherapy; ns, non-significant; OS, overall survival; PD-L1, programmed cell death 1 ligand 1; TMB, tumor mutational burden; WT, wild type. * n = 1798; adjusted by age, sex, race, cancer type, PD-L1, any metastasis, TMB, and histology in the 1L. ^† n = 1016; adjusted by age, sex, race, cancer type, PD-L1, any metastasis, TMB, histology, and drug category in the 1L